Disc Medicine Inc. (IRON)
NASDAQ: IRON
· Real-Time Price · USD
49.68
0.26 (0.53%)
At close: May 01, 2025, 3:59 PM
49.75
0.14%
Pre-market: May 02, 2025, 05:07 AM EDT
Company Description
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases.
It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis.
The company is based in Watertown, Massachusetts.
Disc Medicine Inc.
| Country | United States |
| IPO Date | Aug 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 84 |
| CEO | Sonia Razzetti Ph.D. |
Contact Details
Address: 321 Arsenal Street Watertown, Massachusetts United States | |
| Website | https://www.discmedicine.com |
Stock Details
| Ticker Symbol | IRON |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001901203 |
| CUSIP Number | |
| ISIN Number | US2546041011 |
| Employer ID | 00-0000000 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven Caffé M.D. | Chief Regulatory Officer |
| Melanie Chin Ph.D. | Vice President of Clinical Development & Head of Medical Affairs |
| Min Wu Ph.D. | Vice President & Head of Innovation |
| Sonia Razzetti Ph.D. | Senior Vice President of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | S-4/A | [Amend] Filing |
| Apr 14, 2025 | S-4/A | [Amend] Filing |
| Apr 07, 2025 | S-4/A | [Amend] Filing |
| Mar 18, 2025 | S-4/A | [Amend] Filing |
| Feb 25, 2025 | 4 | Filing |
| Feb 25, 2025 | 3 | Filing |
| Feb 21, 2025 | 10-K | Annual Report |
| Jan 31, 2025 | SCHEDULE 13G | Filing |
| Jan 28, 2025 | S-4/A | [Amend] Filing |
| Dec 23, 2024 | 8-K | Current Report |